IVBT — Innovation1 Biotech Income Statement

0.000.00%

Last trade - 00:00

FinancialsHighly SpeculativeMicro Cap

Annual income statement for Innovation1 Biotech, fiscal year end - August 31st, USD millions except per share, conversion factor applied.

	C2019 August 31st	2020 August 31st	2021 August 31st	C2022 August 31st	2023 August 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	0.079	0.001	0.003	0	0
Cost of Revenue
Gross Profit	-0.01	-0.002	0.002	0	0
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	0.747	0.806	0.262	40.9	4.68
Operating Profit	-0.668	-0.804	-0.258	-40.9	-4.68
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-0.17	-2.58	1.04	-40.9	-5.99
Net Income After Taxes	-0.17	-2.58	1.04	-40.9	-5.99
Net Income Before Extraordinary Items
Net Income	-0.17	-2.58	1.04	-40.9	-5.99
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-0.17	-2.58	1.04	-41.6	-14.1
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-0.295	-10.6	5.63	-0.39	-0.534